Nuclear-Medicine Physician's Notes · Lu-177 n.c.a.
Each card opens a focused post on one aspect of running Lu-177 theranostics in an Indian centre — the carrier-added vs n.c.a. decision, how high specific activity changes peptide dose and dosimetry, and what it means to share one Lu-177 supply line across DOTATATE, PSMA-617 and FAPI clinics.
Lu-177 n.c.a.
Posts in this section. New ones land here as they're added.
DOTATATE for NETs, PSMA-617 for prostate, FAPI for tumour-stroma — three indications sharing one n.c.a. supply chain. What shares upstream, what doesn't share downstream, and three traps that catch first-time programmes.
Read this ChemistrySpecific activity ≥ 3,000 GBq/mg, radionuclidic purity ≥ 99.9 %, radiochemical purity ≥ 99 % — the three numbers that separate genuine n.c.a. from carrier-added Lu-177 marketed as n.c.a., and what changes in the patient when any one is missed.
Read thisWhere next